Ambrx Inc.

Ambrx®, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein-based therapeutics using an expanded genetic code. Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, Ambrx technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophysical properties. We call this process Protein Medicinal Chemistry™.

Protein Medicinal Chemistry™ can optimize any protein or antibody to create potentially best-in-class therapeutics such as long-acting proteins, bi-specifics and antibody drug conjugates. The Ambrx advantage allows us to safely and effectively target cytotoxic agents or recruit effector function to tumor cells (oncology) or modulate biological pathways implicated in disease areas such as autoimmune, metabolic and cardiovascular.

TIMELINE

2003: Ambrx founded, based on technology developed in the laboratory of UC Berkeley Chemistry Professor Peter Schultz.

2016: Ambrx was acquired by Shanghai Fosun Pharmaceutical Group, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech.

2021: the company launched its initial public offering on the Nasdaq stock exchange under the ticker symbol of AMAM.

2024: Ambrx reached an agreement to be acquired by Johnson & Johnson (NYS: JNJ) .

John Anderson, Jason Chin, Brad Herberich, David Liu, Thomas Magliery, Eric Meggers, Ryan Mehl, Miro Pastmak, Stephen Santoro, Peter Schultz, Lei Wang, Zhiweng Zhang